Iterum Therapeutics PLC (ITRM)
| Market Cap | 77.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.46M |
| Shares Out | 20.39M |
| EPS (ttm) | -3.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $1.45 |
| Previous Close | $1.58 |
| Change ($) | -0.13 |
| Change (%) | -8.23% |
| Day's Open | 1.40 |
| Day's Range | 1.34 - 1.53 |
| Day's Volume | 13,871,866 |
| 52-Week Range | 0.46 - 4.38 |
-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 --
DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generati...
--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities --
Trading on Nasdaq Capital Market is expected to begin on December 23, 2020 Trading on Nasdaq Capital Market is expected to begin on December 23, 2020
Bilayer tablet patent application could provide U.S. patent coverage for Iterum's commercial formulation through 2039, if granted Bilayer tablet patent application could provide U.S. patent co...
Iterum Therapeutics (ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. The post Iterum Therapeutics News: Why ITRM Stock Is Rocketing Hig...
-- F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved - - - - Potential Approval Q3 2021 with Priority Review --
NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020
DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies
Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies
--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical compan...
DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gen...
DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gen...
DUBLIN, Ireland and CHICAGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...
DUBLIN, Ireland and CHICAGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...
--Meeting with FDA Scheduled for end of Q3-- --Meeting with FDA Scheduled for end of Q3--
DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...
DUBLIN, Ireland and CHICAGO, June 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral anti...
Sulopenem demonstrates superiority in treatment of patients with quinolone resistant pathogens
DUBLIN, Ireland and CHICAGO, June 15, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug r...
DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and ...
Study did not meet its primary endpoint Study did not meet its primary endpoint
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors --
DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next gene...
Topline results expected in Q1 2020 Topline results expected in Q1 2020
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem anti...
Topline results expected in Q1 2020 Topline results expected in Q1 2020
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahea...
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -17.68% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for...
Iterum Therapeutics PLC (ITRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
As of late, it has definitely been a great time to be an investor in Iterum Therapeutics.
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
| Industry Biotechnology | IPO Date May 25, 2018 |
| CEO Corey N. Fishman | Employees 44 |
| Stock Exchange NASDAQ | Ticker Symbol ITRM |
Financial Performance
In 2019, ITRM's revenue was $37,000, a decrease of -95.74% compared to the previous year's $869,000. Losses were -$103.13 million, 33.8% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for ITRM stock is "Sell." The 12-month stock price forecast is 1.75, which is an increase of 20.69% from the latest price.